The NWHN applauds the court’s decision, but encourages the public to stay vigilant.
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Contact: Evita Almassi, email@example.com or 425-749-1886 The FDA announced that it is reviewing its restrictions on mifepristone, a medication used for miscarriage…
In light of the recent decision by the U.S. government to resume using Johnson & Johnson vaccines in the race to protect vulnerable people from COVID-19, we are struck by the disparity between publicly disclosed information about the J&J vaccine…
Washington D.C. — As a national women’s health organization, we know that health justice demands racial justice. Being protected against racially motivated police violence is a health issue. This guilty on all counts verdict today is only one small step…
Late last night, the FDA announced that, effective immediately, both medication abortion and miscarriage patients would be able to access mifepristone via delivery from their providers or through mail-order pharmacies. This tremendous victory will ensure that patients and providers are protected during the pandemic.
We at the National Women’s Health Network are deeply concerned for the safety of our community members across the country as violence toward Asian Americans has escalated over the past year. We have said before and we will say it again. Health justice demands racial justice.
After more than twenty years, Cindy Pearson announced today she is stepping down as Executive Director of the National Women’s Health Network.
Last night, the U.S. Supreme Court reinstated the U. S. Food and Drug Administration’s medically unjustified requirement that people travel to a certified facility simply to pick up abortion pills that they are then allowed to safely take at home.
The NWHN ultimately applauds the FDA Advisory Committee’s decision, but believes that transparency now and going forward is key. We urge the FDA to keep the public informed about the vaccine’s safety, efficacy, and side effects as it is distributed at scale. Further, we urge other vaccine sponsors seeking authorization to submit robust data for all deeply impacted populations. Read our full statement here.